Q-omics provides the consensus-scored LMBR1L profile across patient tissues and cancer cell-line models. LMBR1L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LMBR1L is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LMBR1L RNA expression shows 20,083 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where LMBR1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMBR1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMBR1L survival associations across molecular data types. LMBR1L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMBR1L RNA expression–survival associations across cancer types. High LMBR1L expression shows unfavorable associations in KIRC, LIHC, ACC, COAD and KIRP, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LMBR1L RNA expression.
This table summarizes LMBR1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LMBR1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMBR1L shows lower tumor expression in KICH and higher tumor expression in KIRC, THCA, LIHC, KIRP and COAD. The KIRC box plot shows higher LMBR1L RNA expression in tumor versus normal tissue (log2 FC = +1.129, t-test p < 0.001).
This table shows molecular features associated with LMBR1L in patient tissues and cancer cell lines. In patient samples, LMBR1L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LMBR1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
